The Learning Portal will be under maintenance Monday, 6 December between 6 AM and 5 PM EST. Portal functionality will be unavailable during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > The EU Paediatric Regulation: Operational & Strategic Considerations (Industry Perspective)

The EU Paediatric Regulation: Operational & Strategic Considerations (Industry Perspective)

Posted 01 March 2008

New legislation, Regulation (EC) No 1901/20061, 2 (the Paediatric Regulation), governing the development and regulatory approval of medicines in children became effective in Europe in January 2007. The Paediatric Regulation imposes significant obligations on the pharmaceutical industry to address the potential need for paediatric development as a prerequisite for approval in the adult population. In return, companies are offered incentives for addressing the challenge of pharmaceutical development in the paediatric population. The regulation applies to all medicinal products for human use except generic products, biosimilar products, products authorised by well-established use, and homeopathic and traditional herbal medicines. While the regulation entered into force in January 2007, transitional provisions apply, i.e., the paediatric obligation applies to new medicines not previously approved in the EU from 26 July 2008, and to line extensions of authorised on-patent medicines from 26 January 2009.


© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.